David,
We need contrarians.
In a few months the charts will show the truth.
In all likelihood there is a percentage of
the biotech crush affecting DMX; but, not as
much as the stampede coming when Dimethaid
makes announcement after announcement and
then turns on the solid tap into that multi
billion dollar Arthritis market. I doubt
half the Bio's drawing interest right now
will succeed at their business plans and am
near certain the Dimethaid will.
Dimethaid meets all the criteria on paper:
-flush with cash
-product at/near approvals
-big drug firm relationships
-few hurdles (manufacturing/inspection/translations)
-sound management
-no hint of hype
-other products at least under development
Look at the fungal product. What would you pay as
lets say Glaxo/W to revolutionize this $1.5 billion
market knowing the carrier achieves what has always
blocked an efficient/safe cure?
Whoever comes out with this sells 750 million US
minimum first 12 months. It'll be the only thing in
the market that actually works and as we all know
I speak from personal experience as do others here.
Dimethaid could hardly be in a better position thanks
to the people there.
We're watching for the manufacturing solution, then
capacity, the details of the partnership deals, the
UK labelling, price positioning, fungal product
timeline, etc, etc. Nothing really showstopping.
Lets point out for the new investors here, (there's
bound to be a big bunch), that DMX only has the
facilities inspection left in the FDA approval
process for Pennsaid as a major hurdle.
I hear your point David, but, I'm not buying. The
placement was oversold. Those 2.5 million shares
are up over 100% in a little over a month.
I realize you're just presenting an argument and know
all this; but, not everybody reading this does.
Plus it hasn't exactly hurt that we keep reminding
ourselves of the facts.
Last point. I expect a 200% premium on any buyout
offer. So no less than $26 if the offer is tomorrow.
(No I haven't heard anything).
All the best,
Conan the librarian |
